Latest Attention-deficit hyperactivity disorder management Stories
PLYMOUTH MEETING, Pa., Nov.
INTUNIV, recently approved by the FDA as the first nonscheduled alpha-2A agonist indicated for the treatment of ADHD in children and adolescents, will soon be available in pharmacies nationwide.
Following is a summary of the key Shire scientific presentations.
HONOLULU, Oct. 29 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced new study results on INTUNIV(TM) (guanfacine) Extended Release Tablets, at a major psychiatric medical meeting today.
NEW YORK, Sept.
WALTHAM, Mass., Sept.
Low levels of dopamine markers may underlie symptoms; implications for treatment.
- A person or thing gazed at with wonder or curiosity, especially of a scornful kind.